Premium
Adjuvant immunotherapy for melanoma
Author(s) -
Thomas Daniel,
Bello Danielle M.
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26329
Subject(s) - medicine , pembrolizumab , ipilimumab , nivolumab , melanoma , adjuvant , immunotherapy , oncology , lymph node , adjuvant therapy , disease , surgery , cancer , cancer research
Abstract Surgical resection is the treatment for early cutaneous melanoma and is often curative. Some patients, however, will subsequently relapse. High‐risk features in the primary tumor and regional lymph node metastasis highlight patient subsets that are at increased risk for recurrent disease. Immunotherapy in the form of checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have been shown to improve recurrence‐free survival for node‐positive melanoma in the adjuvant setting and will be the focus of this review.